Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05380557 · ClinicalTrials.gov registry record
ARTEMIS: Study of Patients With Early Stage Pancreatic Cancer Who Have Undergone Genetic Testing
A clinical trial, sponsored by Invitae Corporation.
- Terminated
- Registry status
- 2
- Enrollment target
NCT05380557 is a clinical trial that was terminated before completion, run by Invitae Corporation. The registered enrollment target is 2 participants.
The verdict
NCT05380557 was terminated before completion, sponsored by Invitae Corporation.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
This study includes participants with pancreatic cancer who are undergoing genetic testing at Invitae related to their diagnosis of pancreatic cancer. Our goal in this study is two-fold. First, we would like to research whether any inherited changes in genes may be associated with pancreatic cancer. Second, we would like to learn more about patient experiences with genetic testing, such as patient understanding of the testing, health-related actions taken (or planned to take) as a result of testing, communication and action of family members based on test results, and psychological impact of testing. This research study involves allowing collection of tumor tissue (from a prior biopsy and/or surgery), a blood sample, and sending surveys to participants for their opinion on the impact of the genetic testing as well as clinicians for relevant baseline and medical history information.
Interventions
- DIAGNOSTIC_TEST Germline genetic testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-08-23 |
| Est. Completion | 2022-09-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05380557
The ClinicalTrials.gov registry entry for NCT05380557 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Invitae Corporation, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Germline genetic testing is the first listed.
NCT05380557 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05380557 about?
NCT05380557 is a clinical study titled "ARTEMIS: Study of Patients With Early Stage Pancreatic Cancer Who Have Undergone Genetic Testing". This study includes participants with pancreatic cancer who are undergoing genetic testing at Invitae related to their diagnosis of pancreatic cancer. Our goal in this study is two-fold. First, we would like to research whether any inherited changes in genes may be associated with pancreatic cancer...
What is the current status of trial NCT05380557?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2021-08-23. Estimated completion is 2022-09-06.
What interventions are being tested in trial NCT05380557?
The interventions under investigation include: Germline genetic testing (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05380557?
This trial is sponsored by Invitae Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.